<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04664153</url>
  </required_header>
  <id_info>
    <org_study_id>C3941002</org_study_id>
    <nct_id>NCT04664153</nct_id>
  </id_info>
  <brief_title>Study To Assess Efficacy, Safety, Tolerability And Pharmacokinetics Of PF-07038124 Ointment In Participants With Atopic Dermatitis Or Plaque Psoriasis</brief_title>
  <acronym>EMPORIA</acronym>
  <official_title>A PHASE 2A, RANDOMIZED, DOUBLE BLIND, VEHICLE CONTROLLED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF PF-07038124 OINTMENT FOR 6 WEEKS IN PARTICIPANTS WITH MILD TO MODERATE ATOPIC DERMATITIS OR PLAQUE PSORIASIS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being conducted to provide data on efficacy, safety, tolerability and PK of&#xD;
      PF-07038124 ointment versus vehicle control in the treatment of mild to moderate AD and mild&#xD;
      to moderate plaque psoriasis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 21, 2020</start_date>
  <completion_date type="Actual">August 18, 2021</completion_date>
  <primary_completion_date type="Actual">August 18, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent change from baseline in Eczema Area and Severity Index (EASI) total score at Week 6</measure>
    <time_frame>Week 6</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent change from baseline in Psoriasis Area and Severity Index (PASI) total score at Week 6</measure>
    <time_frame>Week 6</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of AD participants achieving IGA score of clear (0) or almost clear (1) (on a 5-point scale) and a reduction from baseline of ≥2 points at Week 6.</measure>
    <time_frame>Week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of AD participants achieving EASI 75 (75% improvement from baseline)</measure>
    <time_frame>Week 1, 2, 4, 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of AD participants having ≥4 points of reduction in weekly averages of Peak Pruritus Numerical Rating Scale (PP-NRS) from baseline</measure>
    <time_frame>Week 1, 2, 4, 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in EASI total score</measure>
    <time_frame>Week 1, 2, 4, 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of AD participants achieving IGA score of clear (0) or almost clear (1)</measure>
    <time_frame>Week 1, 2, 4, 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in AD body surface area (BSA)</measure>
    <time_frame>Week 1, 2, 4, 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of psoriasis participants with PGA score of clear (0) or almost clear (1) (on a 5-point scale) and ≥2 points improvement from baseline</measure>
    <time_frame>Week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of psoriasis participants achieving PASI 75 (75% or greater improvement from baseline)</measure>
    <time_frame>Week 1, 2, 4, 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of psoriasis participants who achieved a Psoriasis Symptoms Inventory (PSI) score of 0 (not at all) or 1 (mild) on every item</measure>
    <time_frame>Week 1, 2, 4, 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in PASI scores</measure>
    <time_frame>Week 1, 2, 4, 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in PASI scores</measure>
    <time_frame>Week 1, 2, 4, 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of psoriasis participants with PGA score clear (0) or almost clear (1) and ≥2 points improvement from baseline</measure>
    <time_frame>Week 1, 2, 4, 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in psoriasis BSA</measure>
    <time_frame>Week 1, 2, 4, 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment emergent adverse events (AEs) and serious adverse events (SAEs).</measure>
    <time_frame>Week 1, 2, 4, 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with clinically significant changes from baseline in vital signs</measure>
    <time_frame>Week 1, 2, 4, 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with laboratory abnormalities</measure>
    <time_frame>Week 1, 2, 4, 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with clinically significant treatment-emergent electrocardiogram (ECG) findings</measure>
    <time_frame>Week 1, 2, 4, 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of severity grades in skin tolerability</measure>
    <time_frame>Week 1, 2, 4, 6</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">104</enrollment>
  <condition>Atopic Dermatitis</condition>
  <condition>Plaque Psoriasis</condition>
  <arm_group>
    <arm_group_label>atopic dermatitis - PF-07038124 ointment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>atopic dermatitis - vehicle ointment</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>plaque psoriasis - PF-07038124 ointment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>plaque psoriasis - vehicle ointment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-07038124 ointment</intervention_name>
    <description>PF-07038124 ointment at 0.01% with QD dosing for 6 weeks</description>
    <arm_group_label>atopic dermatitis - PF-07038124 ointment</arm_group_label>
    <arm_group_label>plaque psoriasis - PF-07038124 ointment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle ointment</intervention_name>
    <description>Vehicle ointment with QD dosing for 6 weeks</description>
    <arm_group_label>atopic dermatitis - vehicle ointment</arm_group_label>
    <arm_group_label>plaque psoriasis - vehicle ointment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Atopic Dermatitis (AD): Have been diagnosed with AD for at least 3 months; Have an&#xD;
             Investigator's Global Assessment (IGA) score of 2 (mild), or 3 (moderate); Have AD&#xD;
             covering 5% to 20% (inclusive) of BSA.&#xD;
&#xD;
          -  Plaque psoriasis: Have been diagnosed with plaque psoriasis (psoriasis vulgaris) for&#xD;
             at least 6 months; Have a Physician Global Assessment (PGA) score of 2 (mild), or 3&#xD;
             (moderate); Having plaque psoriasis covering 5% to 15% (inclusive) of BSA.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of skin comorbidities that would interfere with study assessment or response&#xD;
             to treatment.&#xD;
&#xD;
          -  Current or recent history of severe, progressive, or uncontrolled renal, hepatic,&#xD;
             hematological, gastrointestinal, metabolic, endocrine, pulmonary, cardiovascular, or&#xD;
             neurological disease.&#xD;
&#xD;
          -  Other medical or psychiatric condition including recent (within the past year) or&#xD;
             active suicidal ideation/behavior or laboratory abnormality that may increase the risk&#xD;
             of study participation or, in the investigator's judgment, make the participant&#xD;
             inappropriate for the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>First OC Dermatology</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Renaissance Research and Medical Group</name>
      <address>
        <city>Cape Coral</city>
        <state>Florida</state>
        <zip>33991</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Olympian Clinical Research</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moonshine Research Center, Inc.</name>
      <address>
        <city>Doral</city>
        <state>Florida</state>
        <zip>33166</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Neuroscience Solutions</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ForCare Clinical Research</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dawes Fretzin Clinical Research Group, LLC</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46250</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Indiana Clinical Trials Center, PC</name>
      <address>
        <city>Plainfield</city>
        <state>Indiana</state>
        <zip>46168</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Medical Center, New Center One</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M3 Wake Research, Inc.</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Dermatology and Research Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Neuroscience Solutions, Inc. dba CNS Healthcare</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Studies in Dermatology</name>
      <address>
        <city>Cypress</city>
        <state>Texas</state>
        <zip>77433</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Clinical Studies</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Clinical Studies, LTD. LLP</name>
      <address>
        <city>Webster</city>
        <state>Texas</state>
        <zip>77598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Australian Clinical Research Network</name>
      <address>
        <city>Maroubra</city>
        <state>New South Wales</state>
        <zip>2035</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emeritus Research</name>
      <address>
        <city>Camberwell</city>
        <state>Victoria</state>
        <zip>3124</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatrials Research</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 1Y2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lynderm Research Inc.</name>
      <address>
        <city>Markham</city>
        <state>Ontario</state>
        <zip>L3P 1X3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DermEdge Research</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <zip>L5H 1G9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Innovaderm Research Inc.</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H2X 2V1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de Recherche Dermatologique du Quebec metropolitain</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4X7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Specjalistyczny Osrodek Dermatologiczny DERMAL</name>
      <address>
        <city>Bialystok</city>
        <zip>15-453</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mazowieckie Centrum Badań Klinicznych</name>
      <address>
        <city>Grodzisk Mazowiecki</city>
        <zip>05-825</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Angelius Provita</name>
      <address>
        <city>Katowice</city>
        <zip>40-611</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Terapii Współczesnej J.M. Jasnorzewska Spółka Komandytowo-Akcyjna</name>
      <address>
        <city>Lodz</city>
        <zip>90-242</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermedic Jacek Zdybski</name>
      <address>
        <city>Ostrowiec Swietokrzyski</city>
        <zip>27-400</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kliniczny Szpital Wojewódzki nr 1 im. F. Chopina w Rzeszowie</name>
      <address>
        <city>Rzeszow</city>
        <zip>35-055</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ETG Warszawa</name>
      <address>
        <city>Warszawa</city>
        <zip>02-793</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Poland</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=C3941002</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>December 6, 2020</study_first_submitted>
  <study_first_submitted_qc>December 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 11, 2020</study_first_posted>
  <last_update_submitted>September 21, 2021</last_update_submitted>
  <last_update_submitted_qc>September 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>atopic dermatitis, plaque psoriasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Psoriasis</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
    <ipd_url>https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

